NIAID animation explains the ever-changing nature of influenza viruses.
Learn how immunizing a critical portion of a community protects most members of the community.
Vaccines provide safe, cost-effective, and efficient means of preventing illness, disability, and death from infectious diseases. NIAID conducts and supports research on new and improved vaccines and is a worldwide leader in the basic immunology research that underpins all vaccine research and development.
Ebola Vaccine Trial Opens in Liberia—Feb. 2, 2015
Q&A: PREVAIL Phase 2/3 Clinical Trial of Investigational Ebola Vaccines—Feb. 2, 2015
Media Availability: Scientists Report on Trial of Early-Generation Ebola, Marburg Vaccine Candidates—Dec. 23, 2014
Sequential Immunization with VSV-Based Lassa and Ebola Vaccines Does Not Diminish Protection in Monkeys, NIAID Study Finds—Nov. 14 2014
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine—Oct. 22, 2014
Read More: All Vaccine News Releases | News From NIAID-Supported Institutions
Program Announcement: Information about Grants for Research to Advance Vaccine Safety (R01 and R21)
Overcoming Challenges in Staphylococcus aureus Vaccine Development - Meeting Summary, June 7, 2013 (PDF)
Jordan Report: Accelerated Development of Vaccines 2012
Last Updated February 02, 2015